{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:44:00Z","timestamp":1793835840379,"version":"4.6.1"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["22213MFDS421"],"award-info":[{"award-number":["22213MFDS421"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["RS-2025-02213409"],"award-info":[{"award-number":["RS-2025-02213409"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["RS-2023-00217074"],"award-info":[{"award-number":["RS-2023-00217074"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["RS-2024-00507060"],"award-info":[{"award-number":["RS-2024-00507060"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Precision medicine provides a therapeutic framework that addresses the interindividual diversity in tumor genetics, immunological determinants of disease, and immune responsiveness. Among precision approaches, personalized cancer vaccines (PCVs) have gained attention as a promising strategy for inducing tumor-specific immunity by identifying patient-derived neoantigens. Despite encouraging clinical outcomes, the development of PCVs faces major challenges in optimizing antigen selection, delivery, immune activation, and clinical translation. This Review summarizes current advances in PCV research, covering tumor antigen classification, neoantigen prediction algorithms, and the evolution of delivery technologies such as peptide, dendritic cell, DNA, and mRNA-lipid nanoparticle platforms. We highlight the advantages of mRNA-lipid nanoparticle systems that enable rapid manufacturing, potent antigen expression, and integration with immunostimulatory cytokines. Furthermore, we discuss emerging combination strategies involving cytokine engineering and T cell modulation that provide new opportunities to enhance immunogenicity and therapeutic efficacy. Ultimately, we propose that the future maturation of PCVs will require a coordinated process across five interconnected dimensions: (1) advances in neoantigen prediction technologies, (2) rapid delivery of PCVs to patients, (3) an increase in anticancer efficacy through combination therapy strategies, (4) establishment of cost-effective manufacturing processes, and (5) regulatory innovation. In this Review, we conceptualize this multidimensional alignment as \u201cTake Five,\u201d a unifying framework to bring precision, rhythm, and balance to next-generation cancer immunotherapy.<\/jats:p>","DOI":"10.1038\/s12276-026-01807-y","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T09:56:01Z","timestamp":1786614961000},"page":"2550-2561","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Take Five: harmonization in personalized cancer vaccines for cancer immunotherapy"],"prefix":"10.1038","volume":"58","author":[{"given":"Seongje","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jisun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Min","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0974-4343","authenticated-orcid":false,"given":"Jae-Hwan","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"1807_CR1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"1807_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1126\/science.959840","volume":"194","author":"PC Nowell","year":"1976","unstructured":"Nowell, P. C. The clonal evolution of tumor cell populations. Science 194, 23\u201328 (1976).","journal-title":"Science"},{"key":"1807_CR3","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1158\/0008-5472.CAN-12-2217","volume":"72","author":"C Swanton","year":"2012","unstructured":"Swanton, C. Intratumor heterogeneity: evolution through space and time. Cancer Res 72, 4875\u20134882 (2012).","journal-title":"Cancer Res"},{"key":"1807_CR4","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1056\/NEJMp1500523","volume":"372","author":"FS Collins","year":"2015","unstructured":"Collins, F. S. & Varmus, H. A new initiative on precision medicine. N Engl. J Med. 372, 793\u2013795 (2015).","journal-title":"N Engl. J Med"},{"key":"1807_CR5","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1038\/s41390-025-04021-0","volume":"97","author":"S Mani","year":"2025","unstructured":"Mani, S., Lalani, S. R. & Pammi, M. Genomics and multiomics in the age of precision medicine. Pediatr. Res. 97, 1399\u20131410 (2025).","journal-title":"Pediatr. Res."},{"key":"1807_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-021-00169-0","volume":"5","author":"E Martinez-Perez","year":"2021","unstructured":"Martinez-Perez, E., Molina-Vila, M. A. & Marino-Buslje, C. Panels and models for accurate prediction of tumor mutation burden in tumor samples. npj Precis. Oncol. 5, 31 (2021).","journal-title":"npj Precis. Oncol."},{"key":"1807_CR7","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol 20, 651\u2013668 (2020).","journal-title":"Nat. Rev. Immunol"},{"key":"1807_CR8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/nature23093","volume":"547","author":"CJM Melief","year":"2017","unstructured":"Melief, C. J. M. Cancer: precision T-cell therapy targets tumours. Nature 547, 165\u2013167 (2017).","journal-title":"Nature"},{"key":"1807_CR9","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41591-020-01206-4","volume":"27","author":"Z Hu","year":"2021","unstructured":"Hu, Z. et al. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat. Med. 27, 515\u2013525 (2021).","journal-title":"Nat. Med."},{"key":"1807_CR10","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"U Sahin","year":"2017","unstructured":"Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222\u2013226 (2017).","journal-title":"Nature"},{"key":"1807_CR11","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1126\/science.aar7112","volume":"359","author":"U Sahin","year":"2018","unstructured":"Sahin, U. & Tureci, O. Personalized vaccines for cancer immunotherapy. Science 359, 1355\u20131360 (2018).","journal-title":"Science"},{"key":"1807_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","volume":"8","author":"N Xie","year":"2023","unstructured":"Xie, N. et al. Neoantigens: promising targets for cancer therapy. Signal Transduct. Target Ther. 8, 9 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"1807_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00692-9","volume":"12","author":"A Shariati","year":"2024","unstructured":"Shariati, A. et al. mRNA cancer vaccines from bench to bedside: a new era in cancer immunotherapy. Biomark Res. 12, 157 (2024).","journal-title":"Biomark Res"},{"key":"1807_CR14","doi-asserted-by":"publisher","unstructured":"Joyce, S. In Handbook of Cancer and Immunology (Ed: N. Rezaei), Springer, Cham. 1\u201340, https:\/\/doi.org\/10.1007\/978-3-030-80962-1_38-1 (2023).","DOI":"10.1007\/978-3-030-80962-1_38-1"},{"key":"1807_CR15","doi-asserted-by":"publisher","unstructured":"Hao, Q. et al. Development and clinical applications of therapeutic cancer vaccines with individualized and shared neoantigens. Vaccines https:\/\/doi.org\/10.3390\/vaccines12070717 (2024).","DOI":"10.3390\/vaccines12070717"},{"key":"1807_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-60327-811-9_1","volume":"520","author":"JY Zhang","year":"2009","unstructured":"Zhang, J. Y., Looi, K. S. & Tan, E. M. Identification of tumor-associated antigens as diagnostic and predictive biomarkers in cancer. Methods Mol. Biol. 520, 1\u201310 (2009).","journal-title":"Methods Mol. Biol."},{"key":"1807_CR17","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.4161\/hv.29475","volume":"10","author":"RK Bright","year":"2014","unstructured":"Bright, R. K., Bright, J. D. & Byrne, J. A. Overexpressed oncogenic tumor-self antigens. Hum. Vaccin. Immunother 10, 3297\u20133305 (2014).","journal-title":"Hum. Vaccin. Immunother"},{"key":"1807_CR18","doi-asserted-by":"publisher","unstructured":"Feola, S., Chiaro, J., Martins, B. & Cerullo, V. Uncovering the tumor antigen landscape: what to know about the discovery process. Cancers https:\/\/doi.org\/10.3390\/cancers12061660 (2020).","DOI":"10.3390\/cancers12061660"},{"key":"1807_CR19","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.1016\/j.cell.2023.06.020","volume":"186","author":"G Dolton","year":"2023","unstructured":"Dolton, G. et al. Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy. Cell 186, 3333\u20133349.e27 (2023).","journal-title":"Cell"},{"key":"1807_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47909-x","volume":"15","author":"LS Arroyo Muhr","year":"2024","unstructured":"Arroyo Muhr, L. S. et al. Concomitant human papillomavirus (HPV) vaccination and screening for elimination of HPV and cervical cancer. Nat. Commun. 15, 3679 (2024).","journal-title":"Nat. Commun."},{"key":"1807_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60894-z","volume":"16","author":"M Huang","year":"2025","unstructured":"Huang, M. et al. Hepatitis B virus promotes liver cancer by modulating the immune response to environmental carcinogens. Nat. Commun. 16, 5360 (2025).","journal-title":"Nat. Commun."},{"key":"1807_CR22","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/med4.37","volume":"1","author":"H Zhang","year":"2023","unstructured":"Zhang, H. et al. Oncogenic viral antigens for engineered T cell immunotherapy: challenges and opportunities. Med. Adv. 1, 306\u2013317 (2023).","journal-title":"Med. Adv."},{"key":"1807_CR23","first-page":"274","volume":"21","author":"X Li","year":"2023","unstructured":"Li, X. et al. Neoantigen cancer vaccines: a new star on the horizon. Cancer Biol. Med. 21, 274\u2013311 (2023).","journal-title":"Cancer Biol. Med."},{"key":"1807_CR24","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1073\/pnas.85.7.2274","volume":"85","author":"E De Plaen","year":"1988","unstructured":"De Plaen, E. et al. Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum-antigen P91A and identification of the tum-mutation. Proc. Natl. Acad. Sci. USA 85, 2274\u20132278 (1988).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1807_CR25","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/s41587-025-02618-8","volume":"44","author":"AG Keskus","year":"2026","unstructured":"Keskus, A. G. et al. Severus detects somatic structural variation and complex rearrangements in cancer genomes using long-read sequencing. Nat. Biotechnol. 44, 247\u2013257 (2026).","journal-title":"Nat. Biotechnol."},{"key":"1807_CR26","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1007\/s12672-025-01816-9","volume":"16","author":"N Ghoreyshi","year":"2025","unstructured":"Ghoreyshi, N. et al. Next-generation sequencing in cancer diagnosis and treatment: clinical applications and future directions. Discov. Oncol. 16, 578 (2025).","journal-title":"Discov. Oncol."},{"key":"1807_CR27","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41573-021-00387-y","volume":"21","author":"F Lang","year":"2022","unstructured":"Lang, F., Schrors, B., Lower, M., Tureci, O. & Sahin, U. Identification of neoantigens for individualized therapeutic cancer vaccines. Nat. Rev. Drug Discov. 21, 261\u2013282 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1807_CR28","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.cell.2020.09.015","volume":"183","author":"DK Wells","year":"2020","unstructured":"Wells, D. K. et al. Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction. Cell 183, 818\u2013834.e13 (2020).","journal-title":"Cell"},{"key":"1807_CR29","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","volume":"8","author":"T Fan","year":"2023","unstructured":"Fan, T. et al. Therapeutic cancer vaccines: advancements, challenges, and prospects. Signal Transduct. Target Ther. 8, 450 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"1807_CR30","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.semcancer.2023.02.007","volume":"91","author":"T Li","year":"2023","unstructured":"Li, T. et al. Artificial intelligence in cancer immunotherapy: applications in neoantigen recognition, antibody design and immunotherapy response prediction. Semin. Cancer Biol. 91, 50\u201369 (2023).","journal-title":"Semin. Cancer Biol."},{"key":"1807_CR31","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan, M., Hopkins, A. & Jaffee, E. M. Tumor mutational burden and response rate to PD-1 inhibition. N Engl. J Med. 377, 2500\u20132501 (2017).","journal-title":"N Engl. J Med."},{"key":"1807_CR32","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdy495","volume":"30","author":"TA Chan","year":"2019","unstructured":"Chan, T. A. et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 30, 44\u201356 (2019).","journal-title":"Ann Oncol"},{"key":"1807_CR33","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.3389\/fimmu.2018.01499","volume":"9","author":"Y Guo","year":"2018","unstructured":"Guo, Y., Lei, K. & Tang, L. Neoantigen vaccine delivery for personalized anticancer immunotherapy. Front Immunol. 9, 1499 (2018).","journal-title":"Front Immunol"},{"key":"1807_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.696791","volume":"12","author":"AJ Stephens","year":"2021","unstructured":"Stephens, A. J., Burgess-Brown, N. A. & Jiang, S. Beyond just peptide antigens: the complex world of peptide-based cancer vaccines. Front Immunol. 12, 696791 (2021).","journal-title":"Front Immunol"},{"key":"1807_CR35","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","volume":"7","author":"L Wang","year":"2022","unstructured":"Wang, L. et al. Therapeutic peptides: current applications and future directions. Signal Transduct. Target Ther. 7, 48 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"1807_CR36","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1021\/acs.jproteome.9b00874","volume":"19","author":"B Reynisson","year":"2020","unstructured":"Reynisson, B. et al. Improved prediction of MHC II antigen presentation through integration and motif deconvolution of mass spectrometry MHC eluted ligand data. J Proteome Res. 19, 2304\u20132315 (2020).","journal-title":"J Proteome Res."},{"key":"1807_CR37","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217\u2013221 (2017).","journal-title":"Nature"},{"key":"1807_CR38","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/nrg2432","volume":"9","author":"MA Kutzler","year":"2008","unstructured":"Kutzler, M. A. & Weiner, D. B. DNA vaccines: ready for prime time? Nat. Rev. Genet 9, 776\u2013788 (2008).","journal-title":"Nat. Rev. Genet"},{"key":"1807_CR39","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13046-019-1154-7","volume":"38","author":"A Lopes","year":"2019","unstructured":"Lopes, A., Vandermeulen, G. & Preat, V. Cancer DNA vaccines: current preclinical and clinical developments and future perspectives. J Exp. Clin Cancer Res. 38, 146 (2019).","journal-title":"J Exp. Clin Cancer Res."},{"key":"1807_CR40","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines \u2014 a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261\u2013279 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1807_CR41","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou, X., Zaks, T., Langer, R. & Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078\u20131094 (2021).","journal-title":"Nat. Rev. Mater."},{"key":"1807_CR42","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.copbio.2021.09.016","volume":"73","author":"E Kon","year":"2022","unstructured":"Kon, E., Elia, U. & Peer, D. Principles for designing an optimal mRNA lipid nanoparticle vaccine. Curr. Opin Biotechnol. 73, 329\u2013336 (2022).","journal-title":"Curr. Opin Biotechnol."},{"key":"1807_CR43","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41578-022-00529-7","volume":"8","author":"SA Dilliard","year":"2023","unstructured":"Dilliard, S. A. & Siegwart, D. J. Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs. Nat. Rev. Mater. 8, 282\u2013300 (2023).","journal-title":"Nat. Rev. Mater."},{"key":"1807_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01335-5","volume":"20","author":"L Miao","year":"2021","unstructured":"Miao, L., Zhang, Y. & Huang, L. mRNA vaccine for cancer immunotherapy. Mol. Cancer 20, 41 (2021).","journal-title":"Mol. Cancer"},{"key":"1807_CR45","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","volume":"55","author":"R Verbeke","year":"2022","unstructured":"Verbeke, R., Hogan, M. J., Lore, K. & Pardi, N. Innate immune mechanisms of mRNA vaccines. Immunity 55, 1993\u20132005 (2022).","journal-title":"Immunity"},{"key":"1807_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1246682","volume":"14","author":"B Wang","year":"2023","unstructured":"Wang, B., Pei, J., Xu, S., Liu, J. & Yu, J. Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities. Front Immunol 14, 1246682 (2023).","journal-title":"Front Immunol"},{"key":"1807_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-06033-6","volume":"23","author":"Q Fu","year":"2025","unstructured":"Fu, Q. et al. mRNA vaccines in the context of cancer treatment: from concept to application. J Transl. Med. 23, 12 (2025).","journal-title":"J Transl. Med."},{"key":"1807_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202002022","volume":"10","author":"C Dobrowolski","year":"2021","unstructured":"Dobrowolski, C., Paunovska, K., Hatit, M. Z. C., Lokugamage, M. P. & Dahlman, J. E. Therapeutic RNA delivery for COVID and other diseases. Adv. Healthc Mater. 10, e2002022 (2021).","journal-title":"Adv. Healthc Mater."},{"key":"1807_CR49","doi-asserted-by":"publisher","unstructured":"Lopes de Abreu, A. d. J. et al. Unpacking the mRNA supply chain: challenges and opportunities for global health. Vaccines https:\/\/doi.org\/10.3390\/vaccines14040324 (2026).","DOI":"10.3390\/vaccines14040324"},{"key":"1807_CR50","doi-asserted-by":"publisher","first-page":"17","DOI":"10.32607\/actanaturae.27707","volume":"17","author":"AA Ibragimova","year":"2025","unstructured":"Ibragimova, A. A. et al. mRNA-based personalized cancer vaccines: opportunities, challenges and outcomes. Acta Naturae 17, 17\u201337 (2025).","journal-title":"Acta Naturae"},{"key":"1807_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2026.189577","volume":"1881","author":"P Garg","year":"2026","unstructured":"Garg, P., Salgia, R. & Singhal, S. S. mRNA-based cancer vaccines: a new frontier in personalized immunotherapy. Biochim. Biophys. Acta Rev. Cancer 1881, 189577 (2026).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"1807_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00760-5","volume":"8","author":"C Xie","year":"2023","unstructured":"Xie, C., Yao, R. & Xia, X. The advances of adjuvants in mRNA vaccines. npj Vaccines 8, 162 (2023).","journal-title":"npj Vaccines"},{"key":"1807_CR53","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.immuni.2023.09.005","volume":"56","author":"JR Giles","year":"2023","unstructured":"Giles, J. R., Globig, A. M., Kaech, S. M. & Wherry, E. J. CD8+ T cells in the cancer-immunity cycle. Immunity 56, 2231\u20132253 (2023).","journal-title":"Immunity"},{"key":"1807_CR54","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41577-021-00574-3","volume":"22","author":"M Philip","year":"2022","unstructured":"Philip, M. & Schietinger, A. CD8+ T cell differentiation and dysfunction in cancer. Nat. Rev. Immunol. 22, 209\u2013223 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"1807_CR55","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","volume":"124","author":"H Raskov","year":"2021","unstructured":"Raskov, H., Orhan, A., Christensen, J. P. & Gogenur, I. Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. Br J Cancer 124, 359\u2013367 (2021).","journal-title":"Br J Cancer"},{"key":"1807_CR56","doi-asserted-by":"publisher","unstructured":"Hinks, T. S. C., Hoyle, R. D. & Gelfand, E. W. CD8+ Tc2 cells: underappreciated contributors to severe asthma. Eur. Respir. Rev. https:\/\/doi.org\/10.1183\/16000617.0092-2019 (2019).","DOI":"10.1183\/16000617.0092-2019"},{"key":"1807_CR57","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1038\/s12276-023-01105-x","volume":"55","author":"CH Koh","year":"2023","unstructured":"Koh, C. H., Lee, S., Kwak, M., Kim, B. S. & Chung, Y. CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential. Exp. Mol. Med. 55, 2287\u20132299 (2023).","journal-title":"Exp. Mol. Med."},{"key":"1807_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.708874","volume":"12","author":"S Mishra","year":"2021","unstructured":"Mishra, S., Srinivasan, S., Ma, C. & Zhang, N. CD8+ regulatory T cell \u2014 a mystery to be revealed. Front Immunol. 12, 708874 (2021).","journal-title":"Front Immunol."},{"key":"1807_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s12575-025-00265-6","volume":"27","author":"X Su","year":"2025","unstructured":"Su, X. et al. Mechanisms of T-cell depletion in tumors and advances in clinical research. Biol. Proced Online 27, 5 (2025).","journal-title":"Biol. Proced Online"},{"key":"1807_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2023.102345","volume":"83","author":"E Bawden","year":"2023","unstructured":"Bawden, E. & Gebhardt, T. The multifaceted roles of CD4+ T cells and MHC class II in cancer surveillance. Curr. Opin Immunol. 83, 102345 (2023).","journal-title":"Curr. Opin Immunol."},{"key":"1807_CR61","doi-asserted-by":"publisher","unstructured":"Crater, J. M., Dunn, D. C., Nixon, D. F. & Furler O\u2019Brien, R. L. A history and atlas of the human CD4+ T helper cell. Biomedicines https:\/\/doi.org\/10.3390\/biomedicines11102608 (2023).","DOI":"10.3390\/biomedicines11102608"},{"key":"1807_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-025-00807-w","volume":"13","author":"J Pu","year":"2025","unstructured":"Pu, J. et al. T cells in cancer: mechanistic insights and therapeutic advances. Biomark Res. 13, 97 (2025).","journal-title":"Biomark Res."},{"key":"1807_CR63","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41417-020-0183-x","volume":"28","author":"RE Tay","year":"2021","unstructured":"Tay, R. E., Richardson, E. K. & Toh, H. C. Revisiting the role of CD4+ T cells in cancer immunotherapy \u2014 new insights into old paradigms. Cancer Gene. Ther. 28, 5\u201317 (2021).","journal-title":"Cancer Gene. Ther."},{"key":"1807_CR64","doi-asserted-by":"publisher","DOI":"10.4110\/in.2023.23.e41","volume":"23","author":"P Topchyan","year":"2023","unstructured":"Topchyan, P., Lin, S. & Cui, W. The role of CD4 T cell help in CD8 T cell differentiation and function during chronic infection and cancer. Immune Netw. 23, e41 (2023).","journal-title":"Immune Netw."},{"key":"1807_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.867189","volume":"13","author":"M Cenerenti","year":"2022","unstructured":"Cenerenti, M., Saillard, M., Romero, P. & Jandus, C. The era of cytotoxic CD4 T cells. Front Immunol 13, 867189 (2022).","journal-title":"Front Immunol"},{"key":"1807_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2023.102330","volume":"83","author":"AM Macy","year":"2023","unstructured":"Macy, A. M., Herrmann, L. M., Adams, A. C. & Hastings, K. T. Major histocompatibility complex class II in the tumor microenvironment: functions of nonprofessional antigen-presenting cells. Curr. Opin. Immunol. 83, 102330 (2023).","journal-title":"Curr. Opin. Immunol."},{"key":"1807_CR67","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1084\/jem.20091918","volume":"207","author":"SA Quezada","year":"2010","unstructured":"Quezada, S. A. et al. Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp. Med. 207, 637\u2013650 (2010).","journal-title":"J Exp. Med."},{"key":"1807_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102383","volume":"106","author":"H Fritah","year":"2022","unstructured":"Fritah, H., Rovelli, R., Chiang, C. L. & Kandalaft, L. E. The current clinical landscape of personalized cancer vaccines. Cancer Treat Rev. 106, 102383 (2022).","journal-title":"Cancer Treat Rev."},{"key":"1807_CR69","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber, J. S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403, 632\u2013644 (2024).","journal-title":"Lancet"},{"key":"1807_CR70","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144\u2013150 (2023).","journal-title":"Nature"},{"key":"1807_CR71","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","volume":"639","author":"Z Sethna","year":"2025","unstructured":"Sethna, Z. et al. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. Nature 639, 1042\u20131051 (2025).","journal-title":"Nature"},{"key":"1807_CR72","doi-asserted-by":"publisher","unstructured":"Jeng, L. B., Liao, L. Y., Shih, F. Y. & Teng, C. F. Dendritic-cell-vaccine-based immunotherapy for hepatocellular carcinoma: clinical trials and recent preclinical studies. Cancers https:\/\/doi.org\/10.3390\/cancers14184380 (2022).","DOI":"10.3390\/cancers14184380"},{"key":"1807_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.117858","volume":"184","author":"M Sheykhhasan","year":"2025","unstructured":"Sheykhhasan, M. et al. Revolutionizing cancer treatment: the power of dendritic cell-based vaccines in immunotherapy. Biomed. Pharmacother 184, 117858 (2025).","journal-title":"Biomed. Pharmacother"},{"key":"1807_CR74","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-10-3126","volume":"17","author":"MA Cheever","year":"2011","unstructured":"Cheever, M. A. & Higano, C. S. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res. 17, 3520\u20133526 (2011).","journal-title":"Clin Cancer Res."},{"key":"1807_CR75","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s40259-015-0140-7","volume":"29","author":"S Jaroslawski","year":"2015","unstructured":"Jaroslawski, S. & Toumi, M. Sipuleucel-T (Provenge((R))) \u2014 autopsy of an innovative paradigm change in cancer treatment: why a single-product Biotech Company failed to capitalize on its breakthrough invention. BioDrugs 29, 301\u2013307 (2015).","journal-title":"BioDrugs"},{"key":"1807_CR76","doi-asserted-by":"publisher","first-page":"e1207842","DOI":"10.1080\/2162402X.2016.1207842","volume":"5","author":"TH Borch","year":"2016","unstructured":"Borch, T. H. et al. mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma. Oncoimmunology 5, e1207842 (2016).","journal-title":"Oncoimmunology"},{"key":"1807_CR77","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.omto.2020.06.019","volume":"18","author":"ASS Do","year":"2020","unstructured":"Do, A. S. S. et al. CD133 mRNA-loaded dendritic cell vaccination abrogates glioma stem cell propagation in humanized glioblastoma mouse model. Mol. Ther. Oncol. 18, 295\u2013303 (2020).","journal-title":"Mol. Ther. Oncol."},{"key":"1807_CR78","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","volume":"120","author":"P Berraondo","year":"2019","unstructured":"Berraondo, P. et al. Cytokines in clinical cancer immunotherapy. Br J Cancer 120, 6\u201315 (2019).","journal-title":"Br J Cancer"},{"key":"1807_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.114993","volume":"199","author":"B Kong","year":"2023","unstructured":"Kong, B., Kim, Y., Kim, E. H., Suk, J. S. & Yang, Y. mRNA: a promising platform for cancer immunotherapy. Adv. Drug Deliv. Rev. 199, 114993 (2023).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"1807_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01899-4","volume":"22","author":"X Wu","year":"2023","unstructured":"Wu, X. et al. Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects. Mol. Cancer 22, 194 (2023).","journal-title":"Mol. Cancer"},{"key":"1807_CR81","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202506426","volume":"12","author":"S Cho","year":"2025","unstructured":"Cho, S. et al. Rapid-turnaround co-administration of mRNA-based MHC-I and MHC-II-restricted neoantigens enhances immune responses of antigen-specific CD8(+) T cells and anti-cancer efficacy in colorectal cancer. Adv. Sci. 12, e06426 (2025).","journal-title":"Adv. Sci."},{"key":"1807_CR82","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nature14426","volume":"520","author":"S Kreiter","year":"2015","unstructured":"Kreiter, S. et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520, 692\u2013696 (2015).","journal-title":"Nature"},{"key":"1807_CR83","doi-asserted-by":"publisher","unstructured":"Huff, A. L. et al. CD4 T cell-activating neoantigens enhance personalized cancer vaccine efficacy. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.174027 (2023).","DOI":"10.1172\/jci.insight.174027"},{"key":"1807_CR84","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1617654","volume":"16","author":"Y Zhang","year":"2025","unstructured":"Zhang, Y. et al. Advances and challenges in neoantigen prediction for cancer immunotherapy. Front Immunol. 16, 1617654 (2025).","journal-title":"Front Immunol."},{"key":"1807_CR85","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fimmu.2012.00009","volume":"3","author":"C Munz","year":"2012","unstructured":"Munz, C. Antigen processing for MHC class II presentation via autophagy. Front Immunol. 3, 9 (2012).","journal-title":"Front Immunol."},{"key":"1807_CR86","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0666-2","volume":"11","author":"MM Richters","year":"2019","unstructured":"Richters, M. M. et al. Best practices for bioinformatic characterization of neoantigens for clinical utility. Genome Med. 11, 56 (2019).","journal-title":"Genome Med."},{"key":"1807_CR87","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-025-00808-9","volume":"13","author":"Z Wang","year":"2025","unstructured":"Wang, Z., Gu, Y., Sun, X. & Huang, H. Computation strategies and clinical applications in neoantigen discovery towards precision cancer immunotherapy. Biomark Res. 13, 96 (2025).","journal-title":"Biomark Res."},{"key":"1807_CR88","doi-asserted-by":"publisher","DOI":"10.1126\/science.adk3487","volume":"388","author":"ZA Ely","year":"2025","unstructured":"Ely, Z. A. et al. Pancreatic cancer-restricted cryptic antigens are targets for T cell recognition. Science 388, eadk3487 (2025).","journal-title":"Science"},{"key":"1807_CR89","doi-asserted-by":"publisher","unstructured":"Becker, W. & Rathmell, W. K. Vaccines in cancer treatment and prevention: the time is now. J Clin Invest https:\/\/doi.org\/10.1172\/JCI195673 (2025).","DOI":"10.1172\/JCI195673"},{"key":"1807_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2024.101324","volume":"101","author":"F Ruzzi","year":"2025","unstructured":"Ruzzi, F. et al. Cancer vaccines: target antigens, vaccine platforms and preclinical models. Mol. Aspects Med. 101, 101324 (2025).","journal-title":"Mol. Aspects Med."},{"key":"1807_CR91","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-022-00378-0","volume":"10","author":"K Sankar","year":"2022","unstructured":"Sankar, K. et al. The role of biomarkers in personalized immunotherapy. Biomark Res. 10, 32 (2022).","journal-title":"Biomark Res."},{"key":"1807_CR92","doi-asserted-by":"publisher","first-page":"800","DOI":"10.4161\/hv.23032","volume":"9","author":"R Harrop","year":"2013","unstructured":"Harrop, R. Cancer vaccines: identification of biomarkers predictive of clinical efficacy. Hum. Vaccin Immunother 9, 800\u2013804 (2013).","journal-title":"Hum. Vaccin Immunother"},{"key":"1807_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104216","volume":"83","author":"NK Verma","year":"2022","unstructured":"Verma, N. K. et al. Obstacles for T-lymphocytes in the tumour microenvironment: therapeutic challenges, advances and opportunities beyond immune checkpoint. eBioMedicine 83, 104216 (2022).","journal-title":"eBioMedicine"},{"key":"1807_CR94","doi-asserted-by":"publisher","unstructured":"Kim, C. G., Sang, Y. B., Lee, J. H. & Chon, H. J. Combining cancer vaccines with immunotherapy: establishing a new immunological approach. Int. J Mol. Sci. https:\/\/doi.org\/10.3390\/ijms22158035 (2021).","DOI":"10.3390\/ijms22158035"},{"key":"1807_CR95","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.31557\/APJCP.2025.26.8.2741","volume":"26","author":"F Rukhayya","year":"2025","unstructured":"Rukhayya, F. et al. Personalized cancer vaccines in combination therapies: current status and future prospects. Asian Pac. J Cancer Prev. 26, 2741\u20132754 (2025).","journal-title":"Asian Pac. J Cancer Prev."},{"key":"1807_CR96","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13045-025-01670-w","volume":"18","author":"Y Zhou","year":"2025","unstructured":"Zhou, Y., Wei, Y., Tian, X. & Wei, X. Cancer vaccines: current status and future directions. J Hematol Oncol. 18, 18 (2025).","journal-title":"J Hematol Oncol."},{"key":"1807_CR97","doi-asserted-by":"publisher","DOI":"10.4110\/in.2022.22.e2","volume":"22","author":"JB Lee","year":"2022","unstructured":"Lee, J. B., Kim, H. R. & Ha, S. J. Immune checkpoint inhibitors in 10 years: contribution of basic research and clinical application in cancer immunotherapy. Immune Netw. 22, e2 (2022).","journal-title":"Immune Netw."},{"key":"1807_CR98","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3844\/ajisp.2009.65.83","volume":"5","author":"CM Capitini","year":"2009","unstructured":"Capitini, C. M., Fry, T. J. & Mackall, C. L. Cytokines as adjuvants for vaccine and cellular therapies for cancer. Am J Immunol. 5, 65\u201383 (2009).","journal-title":"Am J Immunol."},{"key":"1807_CR99","doi-asserted-by":"publisher","first-page":"1455019","DOI":"10.3389\/fimmu.2024.1455019","volume":"15","author":"Z Li","year":"2024","unstructured":"Li, Z. et al. Local administration of mRNA encoding cytokine cocktail confers potent anti-tumor immunity. Front Immunol. 15, 1455019 (2024).","journal-title":"Front Immunol."},{"key":"1807_CR100","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S1470-2045(25)00096-8","volume":"26","author":"O The Lancet","year":"2025","unstructured":"The Lancet, O. Personalised cancer vaccines and new regulatory struggles. Lancet Oncol. 26, 265 (2025).","journal-title":"Lancet Oncol."},{"key":"1807_CR101","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.ymthe.2020.09.038","volume":"29","author":"CS Shemesh","year":"2021","unstructured":"Shemesh, C. S. et al. Personalized cancer vaccines: clinical landscape, challenges, and opportunities. Mol. Ther. 29, 555\u2013570 (2021).","journal-title":"Mol. Ther."},{"key":"1807_CR102","unstructured":"U.S. Food and Drug Administration. Using Artificial Intelligence & Machine Learning in the Development of Drug & Biological Products: Discussion Paper and Request for Feedback. Federal Register, 88 FR 30313 (2023)."},{"key":"1807_CR103","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/nbt.3932","volume":"35","author":"A Vitiello","year":"2017","unstructured":"Vitiello, A. & Zanetti, M. Neoantigen prediction and the need for validation. Nat. Biotechnol. 35, 815\u2013817 (2017).","journal-title":"Nat. Biotechnol."},{"key":"1807_CR104","unstructured":"United States Pharmacopeia Convention. <71> Sterility Tests. Report No. USP-NF General Chapter <71> (United States Pharmacopeia, 2008)."},{"key":"1807_CR105","unstructured":"EMA. EMA Guideline on Quality, Non-clinical and Clinical Requirements for Investigational Advanced Therapy Medicinal Products in Clinical Trials. Report No. EMA\/CAT\/22473\/2025 (Committee for Advanced Therapies (CAT), EMA, 2025)."},{"key":"1807_CR106","unstructured":"Progressing EMA\u2019s PRIority Medicines Scheme Through New Pilot Features (European Medicines Agency, 2026). https:\/\/www.ema.europa.eu\/en\/documents\/report\/progressing-emas-priority-medicines-scheme-through-new-pilot-features_en.pdf."},{"key":"1807_CR107","unstructured":"Scheineson, M. J. et al. Regenerative Medicine, Gene Therapies, and FDA Regulation. In Proceedings of the 2019 FDLI Annual Conference. Food and Drug Law Institute (FDLI), Washington, DC, USA."},{"key":"1807_CR108","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","volume":"183","author":"PA Ott","year":"2020","unstructured":"Ott, P. A. et al. A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell 183, 347\u2013362.e24 (2020).","journal-title":"Cell"},{"key":"1807_CR109","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/s41591-024-02894-y","volume":"30","author":"M Yarchoan","year":"2024","unstructured":"Yarchoan, M. et al. Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1\/2 trial. Nat. Med. 30, 1044\u20131053 (2024).","journal-title":"Nat. Med."},{"key":"1807_CR110","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41392-020-00448-5","volume":"6","author":"Z Ding","year":"2021","unstructured":"Ding, Z. et al. Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer. Signal Transduct. Target Ther. 6, 26 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"1807_CR111","doi-asserted-by":"publisher","first-page":"691605","DOI":"10.3389\/fimmu.2021.691605","volume":"12","author":"Z Chen","year":"2021","unstructured":"Chen, Z. et al. A neoantigen-based peptide vaccine for patients with advanced pancreatic cancer refractory to standard treatment. Front Immunol. 12, 691605 (2021).","journal-title":"Front Immunol."},{"key":"1807_CR112","doi-asserted-by":"publisher","unstructured":"Wu, A. A. et al. Personalizing DNA cancer vaccines. J Pers. Med. https:\/\/doi.org\/10.3390\/jpm15100474 (2025).","DOI":"10.3390\/jpm15100474"},{"key":"1807_CR113","doi-asserted-by":"publisher","first-page":"101516","DOI":"10.1016\/j.xcrm.2024.101516","volume":"5","author":"J Ingels","year":"2024","unstructured":"Ingels, J. et al. Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum. Cell Rep. Med. 5, 101516 (2024).","journal-title":"Cell Rep. Med."},{"key":"1807_CR114","doi-asserted-by":"publisher","first-page":"CT141","DOI":"10.1158\/1538-7445.AM2024-CT141","volume":"84","author":"JE Bauman","year":"2024","unstructured":"Bauman, J. E. et al. Abstract CT141: mRNA-4157 (V940) individualized neoantigen therapy (INT) + pembrolizumab (pembro) in advanced unresectable HPV- head & neck carcinoma (HNSCC): clinical & translational analysis. Cancer Res. 84, CT141 (2024).","journal-title":"Cancer Res."},{"key":"1807_CR115","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.ccell.2022.08.003","volume":"40","author":"MM Awad","year":"2022","unstructured":"Awad, M. M. et al. Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. Cancer Cell 40, 1010\u20131026.e11 (2022).","journal-title":"Cancer Cell"}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01807-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01807-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01807-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T09:03:39Z","timestamp":1788339819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01807-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":115,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["1807"],"URL":"https:\/\/doi.org\/10.1038\/s12276-026-01807-y","relation":{},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"14 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}